Join our daily newsletter At The Bell to receive exclusive market insights
- OncoSil Medical (OSL) treats its second patient in a locally advanced pancreatic cancer clinical trial
- The treatment was undertaken in Madrid, where the volunteer underwent a successful resection of a pancreatic tumour using the OncoSil device
- The news follows the company signing a commercial agreement with the hospital for the treatment of patients with locally advanced pancreatic cancer, worth €374,000 (A$554,800)
- OncoSil’s sales team in Spain are continuing to work with other trained hospitals to facilitate further agreements
- OncoSil is up 1.72 per cent, trading at 5.9 cents at 1:34 pm AEST
OncoSil Medical (OSL) has treated its second patient in a locally advanced pancreatic cancer trial.
The treatment was undertaken at The Hospital Universitario de Fuenlabrada in Madrid, Spain, where the patient underwent a successful resection of a LAPC tumour using the OncoSil device.
OncoSil is a targeted radioactive isotope which is implanted directly into a patient’s pancreatic tumours via an endoscopic ultrasound. The treatment is designed to deliver more concentrated and localised beta radiation compared to external beam radiation.
The news follows the company signing a commercial agreement with the hospital for the treatment of patients with locally advanced pancreatic cancer, worth €374,000 (A$554,800).
OncoSil’s CEO and Managing Director Nigel Lange said the company is encouraged by the resection undertaken on the patient who had received the OncoSil device.
“In the PanCO trial, 23.8 per cent of patients who were treated with the OncoSil device were successfully resected which has been demonstrated to improve patient outcomes from this insidious disease,” Nigel Lange said.
“We look forward to working with additional institutions in Spain and throughout Europe, in order to accelerate the use of the OncoSil device for the benefit of patients suffering from LAPC.”
OncoSil’s sales team in Spain are continuing to work with other trained hospitals to facilitate further agreements. This is hoped to enable greater patient access to the OncoSil device treatment in various regions throughout Spain.
OncoSil was up 1.72 per cent, trading at 5.9 cents at 1:34 pm AEST.
